Paris, 22 July 2010 – Novagali Pharma, a pharmaceutical company that develops ophthalmic innovative products for treatment of all segments of the eye, today celebrated its listing on NYSE Euronext Paris.
Novagali Pharma (ticker symbol: NOVA) was admitted to NYSE Euronext by the listing of 6,359,882 existing shares making up its capital, 3,409,092 new shares resulting from the conversion of convertible bonds ('OCABSA') and the exercise of equity warrants ('BSAOCA'), 36,808 new shares granted in connection with the capital increase reserved to employees, and 6,468,750 new shares issued as part of a global offering, after the full exercise of the Over-Allotment Option. The total amount raised was €22 million. The admission and issue price of Novagali Pharma shares was set at €3.40 each. The company’s market capitalization on the day of admission amounted to €55.3 million.